A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease

Inclusion Criteria:

• Clinical diagnosis of TED based on CAS

Exclusion Criteria:

• Decrease in CAS or proptosis of >≥ 2 points or ≥ 2 mm, respectively, in the studyeye between Screening and Study Baseline (Day 1)

• Requiring immediate surgical ophthalmological intervention or planning correctivesurgery or irradiation during the course of the study, in the judgment of theinvestigator

• Identified pre-existing ophthalmic disease that, in the judgment of theinvestigator, would preclude study participation or complicate interpretation ofstudy results, including corneal decompensation unresponsive to medical managementand including ophthalmic diseases that will likely require prohibited therapy duringthe study

• Any serious medical condition or abnormality in clinical laboratory tests that, inthe investigator's judgment, precludes an individual's safe participation in andcompletion of the study

• Pregnant or breastfeeding, or intention of becoming pregnant during the study orwithin 3 months after the final dose of satralizumab